Samuel RaeInvestorPlace Contributor
About Samuel Rae
Samuel is a currency trader, equities analyst, author and contributor to a number of the leading financial market publications including Futures Magazine, FX Trader Magazine and Spreadbet Magazine. Born and educated in the U.K., he currently lives in Barcelona, Spain, with his two dogs, managing a personal portfolio of mid- to high-risk U.S. equities. He specializes in small- to mid-cap biotechnology, energy and mining stocks.
Join InvestorPlace Insights — FREE!
Get actionable advice from our top experts, including the hottest stocks to buy & sell, 401k and retirement tips, market analysis and more!
Virtual reality and augmented reality haven't taken off yet, but these three companies offer stronger pure plays than Facebook or Sony.
Here's a look at three biotech stocks that have at least one treatment prepped to enter pivotal clinical trials soon.
When companies look for gold in America, they do it in Nevada. These four Nevada gold mine projects could be game-changers for the gold miners carrying them out.
Teva's recent migraine drug data, while positive, didn't impress investors. What happened, and should you tussle with TEVA stock?